Premium
Plasma carcinoembryonic antigen in the diagnosis and management of patients with hepatocellular carcinoma
Author(s) -
Melia W. M.,
Johnson P. J.,
Carter Susan,
MunroNeville A.,
Williams Roger
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810815)48:4<1004::aid-cncr2820480425>3.0.co;2-d
Subject(s) - carcinoembryonic antigen , medicine , hepatocellular carcinoma , cirrhosis , gastroenterology , oncofetal antigen , carcinoma , alpha fetoprotein , tumor marker , pathology , cancer , tumor associated antigen , immunotherapy
The value of serial carcinoembryonic antigen (CEA) measurements as a marker of disease progression or in monitoring treatment was investigated in patients with hepatocellular carcinoma. Of 40 patients, including 16 with normal serum alpha‐fetoprotein (AFP) concentrations, 29 (72.5%) had abnormal plasma CEA at presentation. Although this was more common in patients with pre‐existing cirrhosis, the mean and range of plasma CEA were similar in patients with and without pre‐existing hepatic disease. There was no correlation between plasma CEA and any biochemical parameter of hepatic function, although plasma CEA concentrations were significantly lower in patients with well‐differentiated tumors. CEA concentrations increased in 71% of patients who had no response to cytotoxic drugs, but CEA also increased in 62.5% of those patients who did respond. Plasma CEA concentrations were elevated in 62.5% of patients with normal and 79% of patients with raised serum AFP on admission to the hospital. There was no correlation between individual AFP and CEA concentrations. Although elevated plasma CEA levels may be of diagnostic value in patients with hepatocellular carcinoma in the absence of pre‐existing hepatic disease, and in those with normal serum AFP, our findings indicate that it does not behave as a true tumor marker.